---
title: "Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295933699.md"
description: "A new drug, TUDRIQEV™, has been granted accelerated approval by the FDA for use in combination with nivolumab. The drug is scheduled to be launched within the next 60 days. This approval opens up new treatment options for patients, particularly those with certain medical conditions."
datetime: "2026-08-14T12:01:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295933699.md)
  - [en](https://longbridge.com/en/news/295933699.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295933699.md)
generator: "portal-rs"
---

# Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

A new drug, TUDRIQEV™, has been granted accelerated approval by the FDA for use in combination with nivolumab. The drug is scheduled to be launched within the next 60 days. This approval opens up new treatment options for patients, particularly those with certain medical conditions.

### Related Stocks

- [REPL.US](https://longbridge.com/en/quote/REPL.US.md)

## Related News & Research

- [Replimune management to present fireside chat at Cantor Global Healthcare Conference](https://longbridge.com/en/news/297910099.md)
- [MediciNova joins H.C. Wainwright global investment conference in September](https://longbridge.com/en/news/298297429.md)
- [REG - EDX Medical Group - Director/PDMR shareholdings in the Company](https://longbridge.com/en/news/298058813.md)
- [REG - American Century Inv Spire Healthcare Grp - Form 8.3 - Spire Healthcare Group PLC](https://longbridge.com/en/news/298045178.md)
- [REG - Barclays PLC Adv Medical Solutns. - Form 8.3 ADVANCED MEDICAL SOLUTIONS GROUP PLC](https://longbridge.com/en/news/298035944.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**